Evidence map›Paper›PMID 42252578›Full record

ArticleGut microbes2026

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.

Shujing Li, Haiying Ding, Jiaqi Wang, Lingjie Yuan, Ying Zhou, Weiben Xu, Hang Yin, Mengqian Ye, Yuning Sha, Fangyin Li and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shujing LiDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Haiying DingDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Jiaqi WangDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Lingjie YuanCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Ying ZhouDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Weiben XuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Hang YinDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Mengqian YeDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Yuning ShaDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Fangyin LiDepartment of Urology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Yousheng LiuDepartment of Urology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Zhengqin ZhuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Lulu SongCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Xiangyu JinDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Liefeng MaCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Zhajun ZhanCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Libin PanDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Luo FangDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine drugs serve as the cornerstone of prostate cancer treatment. Flutamide, a representative first-generation antiandrogen, has been relegated to the treatment of recurrent prostate cancer due to novel drug development and therapeutic resistance. Our study shows the gut microbiota contributes to this resistance. Specifically, gut bacteria metabolize Flutamide into FLU-6 (a nitroreduction product) and FLU-9 (an acetylation product), involving species like

Indexed as

Androgen AntagonistsAntineoplastic AgentsFlutamideGastrointestinal MicrobiomeProstatic NeoplasmsAnimalsCell Line, TumorEscherichia coliHumansMaleMiceXenograft Model Antitumor AssaysAndrogen AntagonistsAntineoplastic AgentsFlutamideflutamideGut microbiotanitroreductaseprostate cancer

Identifiers

PMID42252578
PMCPMC13248909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.